Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Priya Life Science Medicines register
Registers› Irish medicines ›ARTISS Solutions for Sealant, deep frozen
Medicines register · Ireland

ARTISS Solutions for Sealant, deep frozen

Authorisation PA2299/026/001 · Baxter Holding B.V.

Source: Health Products Regulatory Authority (HPRA), open dataset, CC BY 4.0. HPRA list dated 19 Nov 2026
Licence holder
Baxter Holding B.V. (all products →)
Active substances
Human fibrinogen, Human thrombin, Calcium chloride, Aprotinin
Clinical trials
3 clinical trials →
Dosage form
Solution for sealant
Routes of administration
Epilesional use, Topical use
ATC codes
B02BC, V03AK
First authorised
03/07/2009
Prescription status
Product subject to prescription which may not be renewed (A)
Supply
Supply through pharmacies only
Legal basis
Full application (Article 8(3) of Directive No 2001/83/EC)

Human fibrinogen: supply and approvals

8 authorised products on the HPRA list contain Human fibrinogen. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Human thrombin: supply and approvals

3 authorised products on the HPRA list contain Human thrombin. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
No entry in the BfArM supply notices (checked 19 Nov 2026)

Registers: EU shortages · US shortages · German shortages · EMA approvals

Calcium chloride: supply and approvals

55 authorised products on the HPRA list contain Calcium chloride. Shortage records below are for the substance in the EU, US and German markets and may not affect this Irish product; for Irish supply, check with the HPRA or a pharmacist.

EU shortage (EMA)
No entry in the EMA shortage catalogue (checked 19 Nov 2026)
US shortage (FDA)
No entry in the FDA drug shortage list (checked 19 Nov 2026)
Germany (BfArM)
1 supply notice, e.g. OsvaRen (24 Mar 2025 to 31 Mar 2027)

Registers: EU shortages · US shortages · German shortages · EMA approvals

About this licence

National authorisation (PA). A product authorisation granted by the HPRA for the Irish market. It has been authorised for 17 years (since 3 July 2009). The HPRA list marks it as marketed in Ireland.

Other medicines with Human fibrinogen in Ireland

7 other products on the HPRA list contain Human fibrinogen, from 4 licence holders; 3 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
FIBRYGA, 1 g, powder and solvent for solution for injection/infusionOctapharma (IP)National authorisation (PA)Marketed
TISSEEL Lyo Powder and Solvent for SealantBaxter Holding B.V.National authorisation (PA)Marketed
TISSEEL Ready to use Solutions for SealantBaxter Holding B.V.National authorisation (PA)Marketed
FIBRYGA 2 g powder and solvent for solution for injection/infusionOctapharma (IP)National authorisation (PA)Not marketed
Riastap 1 g Powder for Solution for Injection/InfusionCSL Behring GmbHNational authorisation (PA)Not marketed
VeraSeal 80 mg/ml/500 IU/ml Solutions for sealantInstituto Grifols S.A.Centralised EU authorisationNot stated
VeraSeal 80 mg/ml/500 IU/ml Solutions for sealantInstituto Grifols S.A.Centralised EU authorisationNot stated

Other medicines with Human thrombin in Ireland

2 other products on the HPRA list contain Human thrombin, from 1 licence holder; 2 of them are marked as marketed. Products with the same substance can differ in strength, form, other ingredients and what they are licensed for, so they are not automatically interchangeable.

MedicineLicence holderLicenceStatus
TISSEEL Lyo Powder and Solvent for SealantBaxter Holding B.V.National authorisation (PA)Marketed
TISSEEL Ready to use Solutions for SealantBaxter Holding B.V.National authorisation (PA)Marketed

Other substances in ATC group B02BC

The ATC system groups medicines by the part of the body they act on and their chemistry. On the HPRA list, 2 other active substances share the group B02BC with this product:

Human factor xiii (2) · Fibrinogen (1)

Numbers in brackets are products on the HPRA list. Sharing an ATC group does not mean two medicines can replace each other.

The licence holder

Baxter Holding B.V. holds 73 products on the HPRA list, with 111 different active substances; 62 of the products are marked as marketed.

Shortages and approvals, every Friday

One email a week with ongoing EU and US medicine shortages, new EMA and FDA approvals and clinical trials recruiting in Ireland.

Free. Unsubscribe from any email with one click. See our privacy policy.

This listing is regulatory information, not medical advice — consult the package leaflet, SPC, or a healthcare professional. For the authoritative record see the HPRA register.

How this page is built

The facts on this page are pulled directly from the HPRA's (Health Products Regulatory Authority) official open dataset — they are not written from memory, and nothing here is summarised or edited. Each field below names the dataset it came from, so you can check it yourself.

This page is built automatically: a daily sync job downloads HPRA's published XML export and copies the licence number, holder, active substance(s), dosage form, route, ATC code(s), authorisation date and prescription status directly into this page — no AI drafting and no per-product editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The HPRA data on this page was last retrieved on 20 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.